CN109810198B - 利用免疫球蛋白片段的位点特异性glp-2缀合物 - Google Patents

利用免疫球蛋白片段的位点特异性glp-2缀合物 Download PDF

Info

Publication number
CN109810198B
CN109810198B CN201910158317.0A CN201910158317A CN109810198B CN 109810198 B CN109810198 B CN 109810198B CN 201910158317 A CN201910158317 A CN 201910158317A CN 109810198 B CN109810198 B CN 109810198B
Authority
CN
China
Prior art keywords
glp
group
conjugate
immunoglobulin
fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN201910158317.0A
Other languages
English (en)
Chinese (zh)
Other versions
CN109810198A (zh
Inventor
金承洙
林世荣
郑圣烨
权世昌
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Hanmi Holdings Co Ltd
Original Assignee
Hanmi Holdings Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hanmi Holdings Co Ltd filed Critical Hanmi Holdings Co Ltd
Priority to CN201910158317.0A priority Critical patent/CN109810198B/zh
Publication of CN109810198A publication Critical patent/CN109810198A/zh
Application granted granted Critical
Publication of CN109810198B publication Critical patent/CN109810198B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
CN201910158317.0A 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物 Active CN109810198B (zh)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201910158317.0A CN109810198B (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
KR10-2011-0147684 2011-12-30
KR1020110147684A KR101895047B1 (ko) 2011-12-30 2011-12-30 면역글로불린 단편을 이용한 위치 특이적 글루카곤 유사 펩타이드-2 약물 결합체
CN201910158317.0A CN109810198B (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物
PCT/KR2012/011748 WO2013100704A1 (en) 2011-12-30 2012-12-28 A site-specific glp-2 conjugate using an immunoglobulin fragment
CN201280071002.9A CN104144697A (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
CN201280071002.9A Division CN104144697A (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物

Publications (2)

Publication Number Publication Date
CN109810198A CN109810198A (zh) 2019-05-28
CN109810198B true CN109810198B (zh) 2023-06-06

Family

ID=48698036

Family Applications (2)

Application Number Title Priority Date Filing Date
CN201910158317.0A Active CN109810198B (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物
CN201280071002.9A Pending CN104144697A (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物

Family Applications After (1)

Application Number Title Priority Date Filing Date
CN201280071002.9A Pending CN104144697A (zh) 2011-12-30 2012-12-28 利用免疫球蛋白片段的位点特异性glp-2缀合物

Country Status (9)

Country Link
US (1) US9504757B2 (https=)
EP (1) EP2797621B1 (https=)
JP (1) JP6131490B2 (https=)
KR (1) KR101895047B1 (https=)
CN (2) CN109810198B (https=)
AR (1) AR089506A1 (https=)
ES (1) ES2725805T3 (https=)
TW (1) TWI666219B (https=)
WO (1) WO2013100704A1 (https=)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20130049671A (ko) 2011-11-04 2013-05-14 한미사이언스 주식회사 생리활성 폴리펩타이드 결합체 제조 방법
AR090281A1 (es) * 2012-03-08 2014-10-29 Hanmi Science Co Ltd Proceso mejorado para la preparacion de un complejo polipeptidico fisiologicamente activo
US9949927B2 (en) 2012-04-10 2018-04-24 The Regents Of The University Of California Bis-polymer lipid-peptide conjugates and nanoparticles thereof
WO2015042252A1 (en) * 2013-09-19 2015-03-26 The Regents Of The University Of California Methods of treatment using bis-polymer lipid-peptide conjugates and nanoparticles thereof
US9994616B2 (en) 2013-10-15 2018-06-12 The University Of Tokyo c-Met protein agonist
AU2014364589B2 (en) * 2013-12-18 2020-02-27 The California Institute For Biomedical Research Modified therapeutic agents, stapled peptide lipid conjugates, and compositions thereof
AU2015242657B2 (en) * 2014-03-31 2020-05-21 Hanmi Pharm. Co., Ltd. Method for improving solubility of protein and peptide by using immunoglobulin Fc fragment linkage
KR101825048B1 (ko) * 2014-12-31 2018-02-05 주식회사 제넥신 GLP 및 면역글로불린 하이브리드 Fc 융합 폴리펩타이드 및 이의 용도
MY206271A (en) 2016-07-11 2024-12-06 Opko Biologics Ltd Long-acting coagulation factor vii and methods of producing same
CN107987170B (zh) * 2016-10-27 2018-12-18 浙江道尔生物科技有限公司 一种用于治疗肠道疾病的融合蛋白
US10925930B2 (en) 2017-02-27 2021-02-23 Urigen N.A. Treatment of lower urinary tract epithelium with glucagon like peptide 2
KR102174436B1 (ko) * 2017-08-17 2020-11-04 주식회사 엘지화학 불용성 안료 화합물의 정성분석방법
US20200199192A1 (en) 2017-08-22 2020-06-25 Shire-Nps Pharmaceuticals, Inc. Glp-2 fusion polypeptides and uses for treating and preventing gastrointestinal conditions
CA3084326A1 (en) * 2017-09-28 2019-04-04 Jaehyuk Choi Long-acting conjugates of glp-2 derivatives
US11660328B2 (en) * 2017-11-06 2023-05-30 Takeda Pharmaceutical Company Limited GLP-2 analogs and peptibodies for administration before, during or after surgery
JP2022512688A (ja) * 2018-10-24 2022-02-07 シャイア－エヌピーエス ファーマシューティカルズ インコーポレイテッド Ｇｌｐ－２融合ポリペプチドならびに消化管の状態の処置および予防のための使用
EP3924369A1 (en) * 2019-02-11 2021-12-22 OPKO Biologics Ltd. Long-acting glp-2 analogs
WO2020198604A1 (en) * 2019-03-28 2020-10-01 United States Government As Represented By The Department Of Veterans Affairs Compositions and methods of treating and preventing systemic complications of acute illness
AU2020397917A1 (en) 2019-12-04 2022-06-23 The Scripps Research Institute GLP2 receptor agonists and methods of use
JP7846622B2 (ja) * 2019-12-24 2026-04-15 ハンミ ファーマシューティカル カンパニー リミテッド Ｇｌｐ－２又はその結合体を含む、代謝性骨疾患の予防又は治療用薬学的組成物
EP4144361A4 (en) * 2020-04-03 2024-05-22 Hanmi Pharm. Co., Ltd. PHARMACEUTICAL COMPOSITION FOR THE PREVENTION OR TREATMENT OF MUCOSITIS INDUCED BY RADIOTHERAPY, CHEMOTHERAPY OR A COMBINATION THEREOF, WITH GLP-2 DERIVATIVES OR LONG-ACTING CONJUGATE THEREOF
EP4154869A4 (en) * 2020-05-22 2025-01-22 Hanmi Pharm. Co., Ltd. Liquid formulation of long-acting conjugate of glp-2
CN111560062A (zh) * 2020-05-26 2020-08-21 成都圣诺生物制药有限公司 一种Elisiglutide的制备方法
WO2022159555A1 (en) * 2021-01-20 2022-07-28 The Trustees Of Columbia University In The City Of New York Methods for treating graft-versus-host disease using glp-2 agonists and analogues thereof
MX2023014771A (es) 2021-06-09 2024-03-19 Scripps Research Inst Conjugados peptidicos duales gip/glp-1 de accion prolongada y metodos de uso.

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483041A (zh) * 2000-12-07 2004-03-17 Glp-1融合蛋白
WO2008082274A1 (en) * 2007-01-05 2008-07-10 Hanmi Pharmaceutical Co., Ltd. An insulinotropic complex using an immunoglobulin fragment
WO2010108153A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
JP4046354B2 (ja) 1996-03-18 2008-02-13 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム 増大した半減期を有する免疫グロブリン様ドメイン
US6924264B1 (en) 1999-04-30 2005-08-02 Amylin Pharmaceuticals, Inc. Modified exendins and exendin agonists
US6756480B2 (en) 2000-04-27 2004-06-29 Amgen Inc. Modulators of receptors for parathyroid hormone and parathyroid hormone-related protein
ATE396202T1 (de) 2001-02-16 2008-06-15 Conjuchem Biotechnologies Inc Lang wirkendes glucagon-ähnliches peptid-2 für die behandlung von gastrointestinalen krankheiten und störungen
CN1705681A (zh) * 2002-10-14 2005-12-07 诺沃挪第克公司 Glp－2化合物、制剂及其用途
US20070060512A1 (en) * 2003-03-04 2007-03-15 Homayoun Sadeghi Dipeptidyl-peptidase protected protein
ATE555133T1 (de) 2003-11-13 2012-05-15 Hanmi Holdings Co Ltd Igg fc fragment für einen arzneimittelträger und verfahren zu dessen herstellung
WO2005067368A2 (en) 2003-11-21 2005-07-28 Nps Allelix Corp. Production of glucagon like peptide 2 and analogs
WO2006076471A2 (en) 2005-01-12 2006-07-20 Nobex Corporation Bnp conjugates and methods of use
DE602006020123D1 (de) 2005-05-04 2011-03-31 Zealand Pharma As Glucagon-like-peptide-2- (glp-2-) analoga
WO2007067828A2 (en) * 2005-10-24 2007-06-14 Centocor, Inc. Glp-2 mimetibodies, polypeptides, compositions, methods and uses
BRPI1013626B8 (pt) 2009-03-20 2021-05-25 Hanmi Holdings Co Ltd método para preparar conjugado de polipeptídeo fisiologicamente ativo em sítio específico
KR101746686B1 (ko) * 2010-10-26 2017-06-15 한미사이언스 주식회사 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1483041A (zh) * 2000-12-07 2004-03-17 Glp-1融合蛋白
WO2008082274A1 (en) * 2007-01-05 2008-07-10 Hanmi Pharmaceutical Co., Ltd. An insulinotropic complex using an immunoglobulin fragment
CN101646451A (zh) * 2007-01-05 2010-02-10 韩美药品工业株式会社 使用免疫球蛋白片段的促胰岛素缀合物
WO2010108153A2 (en) * 2009-03-20 2010-09-23 Amgen Inc. Carrier immunoglobulins and uses thereof

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
The therapeutic potential of targeting the glucagon-like peptide-2 receptor in gastrointestinal disease;Hornby 等;《Expert Opinion on Therapeutic Targets》;20110211;第15卷(第5期);第637-646页 *
一种新的胰高血糖素样肽-1类似物及其缓释技术的研究;高智慧;《中国优秀博硕士学位论文全文数据库(博士) 医药卫生科技辑》;20110715(第07（2011）期);E065-7 *

Also Published As

Publication number Publication date
EP2797621A4 (en) 2015-09-02
JP6131490B2 (ja) 2017-05-24
ES2725805T3 (es) 2019-09-27
EP2797621A1 (en) 2014-11-05
TW201333032A (zh) 2013-08-16
CN104144697A (zh) 2014-11-12
JP2015503554A (ja) 2015-02-02
CN109810198A (zh) 2019-05-28
KR20130078634A (ko) 2013-07-10
AR089506A1 (es) 2014-08-27
US20140377290A1 (en) 2014-12-25
TWI666219B (zh) 2019-07-21
WO2013100704A1 (en) 2013-07-04
US9504757B2 (en) 2016-11-29
KR101895047B1 (ko) 2018-09-06
EP2797621B1 (en) 2019-03-06

Similar Documents

Publication Publication Date Title
CN109810198B (zh) 利用免疫球蛋白片段的位点特异性glp-2缀合物
US9072794B2 (en) Long-acting glucagon conjugate and pharmaceutical composition comprising the same for the prevention and treatment of obesity
CA2795291C (en) An insulin conjugate using an immunoglobulin fragment
AU2012263098B2 (en) Composition for treating diabetes comprising long-acting insulin conjugate and long-acting insulinotropic peptide conjugate
TWI658835B (zh) 用於預防或治療非酒精性脂肪肝疾病之醫藥組合物
RU2624129C2 (ru) Способ получения комплекса физиологически активного полипептида
RU2677800C2 (ru) Сайт-специфичный конъюгат инсулина
KR101746686B1 (ko) 면역글로불린 단편을 이용한 글루카곤 유사 펩타이드―２（ｇｌｐ―２）약물 결합체
KR101767570B1 (ko) 항 비만 펩타이드의 지속형 결합체
NZ742400A (en) A conjugate comprising oxyntomodulin and an immunoglobulin fragment, and use thereof

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant